Efficacy and Safety of Non-Vitamin K Anticoagulants for Atrial Fibrillation in Relation to Different Renal Function Levels: A Network Meta-Analysis
Table 3
Characteristics of the included trials.
RE-LY (18113)
ARISTOTLE (18201)
ROCKET-AF (14262)
ENGAGE AF 48 (21105)
Dosing regiments
110 mg bid
150 mg bid
Adjusted
5 mg bid(1)
Adjusted
20 mg qd(2)
Adjusted
30 mg qd(3)
60 mg qd(4)
Adjusted
Median age, years
71.4
71.5
71.6
70
70
73
73
72
72
72
Type of AF, %
Paroxysmal
32.1
32.6
33.8
15.1
15.5
17.5
17.8
25.3
24.9
26.1
Persistent, permanent
67.9
67.4
66.2
84.9
84.4
81.1
80.8
NR
NR
NR
Mean CHADS2 score
2.1
2.2
2.1
2.1
2.1
3.5
3.5
2.8
2.8
2.8
Previous stroke or TIA,%
19.9
20.3
19.8
19.2
19.7
54.9
54.6
28.3
28.1
28.5
Heart failure, %
32.2
31.8
31.9
35.5
35.4
62.6
62.3
57.5
58.2
56.6
Diabetes mellitus, %
23.4
23.1
23.4
25.0
24.9
40.4
39.5
35.8
36.4
36.2
Hypertension, %
78.8
78.9
78.9
87.3
87.6
90.3
90.8
93.6
93.7
93.3
Previous VKA use, %
50.1
50.2
48.6
51.7
57.2
62.3
62.5
58.8
58.8
59.2
Creatinine clearance, %
Normal renal function, % >80 ml/min
32.3
32.0
32.2
41.2
41.4
32.3
31.3
NR
NR
NR
Mild renal function, % (50–80 ml/min)
48.6
48.1
48.5
41.6
41.8
46.6
46.8
NR
NR
NR
Moderate renal function, % (30–50 ml/min
19.4
19.2
19.4
16.5
16.6
21.0
20.6
19.3
19.6
19.0
Mean follow-up years
2.0
2.0
2.0
1.8
1.8
1.9
1.9
2.8
2.8
2.8
(1)2.5 mg bid of patients with two or more of the following criteria: ≥80 years, ≥60 kg, or serum creatinine ≥ 1.5 mg/dl. (2)15 mg qd in patients with creatinine clearance: 30–49 ml/min. (3)15 mg qd for patients with any of the following characteristics at the time of randomization or during the study: eGFR: 30–50 ml/min, weight ≤ 60 kg, or the concomitant use of verapamil or quinidine. (4)30 mg qd for patients with any of the following characteristics at the time of randomization or during the study: eGFR: 30 to 50 ml/min, weight ≤ 60 kg, or the concomitant use of verapamil or quinidine.
